<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
 <result pre="we have identified additional promising antiviral activities against Middle East" exact="Respiratory" post="Syndrome, Chikungunya, Ebola and Marburg which highlights that this"/>
 <result pre="for virus outbreaks such as for the new coronavirus severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). Tilorone has been long"/>
 <result pre="virus outbreaks such as for the new coronavirus severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). Tilorone has been long neglected"/>
 <result pre="outbreaks such as for the new coronavirus severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). Tilorone has been long neglected by"/>
 <result pre="for broad-spectrum antivirals. Key Words Antiviral broad spectrum interferon inducers" exact="respiratory" post="virus infections Funding http://dx.doi.org/10.13039/100006108National Center for Advancing Translational Sciences"/>
 <result pre="antivirals. Key Words Antiviral broad spectrum interferon inducers respiratory virus" exact="infections" post="Funding http://dx.doi.org/10.13039/100006108National Center for Advancing Translational Sciences R21TR001718EkinsSean Funding"/>
 <result pre="Center for Advancing Translational Sciences R21TR001718EkinsSean Funding http://dx.doi.org/10.13039/100000057National Institute of" exact="General" post="Medical Sciences R44GM122196-02A1EkinsSean Introduction In the last 5 years"/>
 <result pre="we are in the midst of a novel coronavirus severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) (3,4) currently spreading globally"/>
 <result pre="are in the midst of a novel coronavirus severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) (3,4) currently spreading globally from"/>
 <result pre="in the midst of a novel coronavirus severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) (3,4) currently spreading globally from China"/>
 <result pre="virus outbreaks generally pales in comparison to the more common" exact="viral" post="infections, such as influenza (5), HIV (6), and HBV"/>
 <result pre="Lavomax®. It is approved for use in Russia for several" exact="viral" post="disease indications (influenza, acute respiratory viral infection, viral hepatitis,"/>
 <result pre="It is approved for use in Russia for several viral" exact="disease" post="indications (influenza, acute respiratory viral infection, viral hepatitis, viral"/>
 <result pre="for use in Russia for several viral disease indications (influenza," exact="acute" post="respiratory viral infection, viral hepatitis, viral encephalitis, myelitis, and"/>
 <result pre="use in Russia for several viral disease indications (influenza, acute" exact="respiratory" post="viral infection, viral hepatitis, viral encephalitis, myelitis, and others),"/>
 <result pre="in Russia for several viral disease indications (influenza, acute respiratory" exact="viral infection," post="viral hepatitis, viral encephalitis, myelitis, and others), and is"/>
 <result pre="for several viral disease indications (influenza, acute respiratory viral infection," exact="viral hepatitis," post="viral encephalitis, myelitis, and others), and is included in"/>
 <result pre="viral disease indications (influenza, acute respiratory viral infection, viral hepatitis," exact="viral encephalitis," post="myelitis, and others), and is included in the list"/>
 <result pre="in the list of vital and essential medicines of the" exact="Russian" post="Federation (10). Tilorone is also registered for human use"/>
 <result pre="Russia, tilorone is also available over the counter in both" exact="adult" post="and child (ages 7 and above) dosages. Tilorone has"/>
 <result pre="for ~20 years as both a prophylaxis and treatment for" exact="viral" post="diseases. The drug has been produced and manufactured at"/>
 <result pre="support possible uses of tilorone against a broad array of" exact="infections" post="including influenza A, influenza B, herpes simplex virus 1,"/>
 <result pre="a broad array of infections including influenza A, influenza B," exact="herpes" post="simplex virus 1, West Nile virus, Mengo virus, Semliki"/>
 <result pre="1, West Nile virus, Mengo virus, Semliki Forest virus, vesicular" exact="stomatitis" post="virus, encephalomyocarditis virus (12–17) and more recently against human"/>
 <result pre="studies outside the US evaluated tilorone as a treatment for" exact="Acute" post="Respiratory Viral Infections (ARVIs), where it demonstrated significantly improved"/>
 <result pre="outside the US evaluated tilorone as a treatment for Acute" exact="Respiratory" post="Viral Infections (ARVIs), where it demonstrated significantly improved patient"/>
 <result pre="the US evaluated tilorone as a treatment for Acute Respiratory" exact="Viral" post="Infections (ARVIs), where it demonstrated significantly improved patient outcomes"/>
 <result pre="US evaluated tilorone as a treatment for Acute Respiratory Viral" exact="Infections" post="(ARVIs), where it demonstrated significantly improved patient outcomes (22–25)."/>
 <result pre="outcomes (22–25). The drug also showed 72% prophylactic efficacy in" exact="respiratory" post="tract infections in humans (26). Tilorone has undergone several"/>
 <result pre="The drug also showed 72% prophylactic efficacy in respiratory tract" exact="infections" post="in humans (26). Tilorone has undergone several clinical trials"/>
 <result pre="humans (26). Tilorone has undergone several clinical trials published in" exact="Russian" post="journals (23,25,27,28). Besides this track record of use in"/>
 <result pre="in mice at 250 mg/kg single oral dose (12) Vesicular" exact="stomatitis" post="vesiculovirus -ssRNA 20% survival but delayed time to death"/>
 <result pre="at 250 mg/kg (21) Despite its history of use for" exact="viral" post="diseases, its activity against EBOV was discovered using a"/>
 <result pre="the compound was tested in a mouse model of EBOV" exact="infection" post="where it was associated with 90-100% survival in a"/>
 <result pre="(MARV) (33) as well Chikungunya virus (CHIK) and Middle Eastern" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV) (Table II) making it a potential"/>
 <result pre="(33) as well Chikungunya virus (CHIK) and Middle Eastern Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV) (Table II) making it a potential broad-spectrum"/>
 <result pre="antiviral therapeutic as it has demonstrated efficacy in preclinical animal" exact="disease" post="models against very diverse viral families including, filovirus, hepadnavirus,"/>
 <result pre="demonstrated efficacy in preclinical animal disease models against very diverse" exact="viral" post="families including, filovirus, hepadnavirus, human herpesvirus, orthomyxovirus, picornavirus, alphavirus,"/>
 <result pre="water soluble, highly permeable, and is able to penetrate the" exact="blood-brain barrier" post="(38) which suggests that it could access sites of"/>
 <result pre="to drug treatment may exacerbate the clinical symptoms of some" exact="viral" post="infections which result in cytokine storms such as influenza"/>
 <result pre="drug treatment may exacerbate the clinical symptoms of some viral" exact="infections" post="which result in cytokine storms such as influenza (40)."/>
 <result pre="work by activating specific innate immune system pathways that suppress" exact="viral" post="replication. One candidate target is the RIG-like receptor (RLR)"/>
 <result pre="the RIG-like receptor (RLR) signaling pathway that can recognize intracellular" exact="viral" post="RNA and induce a cellular response that leads to"/>
 <result pre="protein have been shown to be a critical mediator of" exact="viral" post="replication in mice (44). In vitro binding data shows"/>
 <result pre="Microscale Thermophoresis (MST) Binding Data of Tilorone to the Human" exact="Viral" post="RNA Sensor RIG-I Shows a Low-Affinity (EC50 = 0.5 mM) in"/>
 <result pre="this Cell-Free in vitro Model. Lysosomotropic mechanism Lysosomotropic amines can" exact="diffuse" post="freely and rapidly across the membranes of acidic cytoplasmic"/>
 <result pre="mechanism may also have an important role as tilorone blocks" exact="viral" post="entry. Cationic amphiphilic drugs have been proposed recently as"/>
 <result pre="point for broad spectrum antivirals (48). Fig. 3. Inhibition of" exact="total" post="Fluorescent Intensity/Cell of Lysotracker Red in MCF7 Cells. Lysotracker"/>
 <result pre="Summary While there are many antiviral drugs for several individual" exact="viral" post="diseases e.g. HIV, HBV, influenza etc., there are currently"/>
 <result pre="recent data suggests efficacy in an animal model of EBOV" exact="infection" post="(36) while additional in vitro activities from several groups"/>
 <result pre="use of this molecule as a broad-spectrum treatment of various" exact="viral" post="infections. The preclinical data around this compound and all"/>
 <result pre="(49–51) and a few of these were found to impact" exact="viral" post="entry (51). In addition, there are other broad spectrum"/>
 <result pre="Mechanism of Action (MOA) Tilorone dihydrochloride is an inhibitor of" exact="viral" post="replication in mammalian host cells through activation of innate"/>
 <result pre="be the RIG-I-signaling pathway responsible for the sensing of intracellular" exact="viral" post="RNA and activation of a cellular antiviral response. A"/>
 <result pre="role may be via its lysosomotropic activity which could impact" exact="viral" post="entry. Antiviral Activity EBOV: viral replication EC50 = 230 nM; 100%"/>
 <result pre="lysosomotropic activity which could impact viral entry. Antiviral Activity EBOV:" exact="viral" post="replication EC50 = 230 nM; 100% survival at 30 mg/kg once"/>
 <result pre="mg/kg once daily intraperitoneal (IP) dosing in a mouse Ebola" exact="infection" post="model (36) In vitroactivities*: CHIK (EC50 = 4.2 μM), MERS-CoV (EC50 = 3.7"/>
 <result pre="Virus, Semliki Forest Virus, Vesicular Stomatitus Virus, and West Nile" exact="Fever" post="Virus (8). *In vitro antiviral potencies can vary greatly"/>
 <result pre="Vero 76 cells lack interferon (IFN) pathways and generally show" exact="lower" post="activities for Tilorone. Pharmacology Human Pharmacology: After oral administration,"/>
 <result pre="(70%) and urine (9%). It does not accumulate (24) (11)." exact="Mouse" post="Pharmacokinetics: At 10 mg/kg IP dosing: t1/2 = 19 h; Tmax = 0.25"/>
 <result pre="of EBOV • Post-exposure Prophylaxis of EBOV • Treatment of" exact="acute" post="infections from ZIKV, CHIK, SARS-CoV, MERS-CoV, and/or influenza. Primary"/>
 <result pre="EBOV • Post-exposure Prophylaxis of EBOV • Treatment of acute" exact="infections" post="from ZIKV, CHIK, SARS-CoV, MERS-CoV, and/or influenza. Primary Efficacy"/>
 <result pre="of acute infections from ZIKV, CHIK, SARS-CoV, MERS-CoV, and/or influenza." exact="Primary" post="Efficacy Endpoints Target: 100% efficacy in EBOV animal studies"/>
 <result pre="efficacy in EBOV animal studies with ≤10% survival among controls" exact="Secondary" post="Efficacy Endpoints Target: Broad species coverage (Zaire and Sudan"/>
 <result pre="adults, excluding pregnant and lactating women Contraindications Possible contraindications from" exact="Russian" post="labeling: Hypersensitivity, pregnancy, breastfeeding, children under 7 years. Drug"/>
 <result pre="Compatible with antibiotics and other drugs for the treatment of" exact="viral" post="and bacterial diseases. CYP450 Inhibition Screening: IC50 &amp;gt; 50 μM for"/>
 <result pre="antibiotics and other drugs for the treatment of viral and" exact="bacterial diseases." post="CYP450 Inhibition Screening: IC50 &amp;gt; 50 μM for 1A2, 2C9, 2C19,"/>
 <result pre="assays. Dr. Vadim Makarov is kindly acknowledged for discussions on" exact="Russian" post="antivirals. SE is founder and owner of Collaborations Pharmaceuticals,"/>
 <result pre="Abbreviations CHIKV Chikungunya virus EBOV Ebola virus EMCV Encephalomyocarditis HBV" exact="Hepatitis" post="B Virus HIV Human immunodeficiency virus ICH International Council"/>
 <result pre="Ebola virus EMCV Encephalomyocarditis HBV Hepatitis B Virus HIV Human" exact="immunodeficiency" post="virus ICH International Council for Harmonization of Technical Requirements"/>
 <result pre="Human Use IFN Interferon MARV Marburg virus MERS Middle East" exact="Respiratory" post="Syndrome RIG-I Retinoic acid-inducible gene I SARS Severe Acute"/>
 <result pre="Use IFN Interferon MARV Marburg virus MERS Middle East Respiratory" exact="Syndrome" post="RIG-I Retinoic acid-inducible gene I SARS Severe Acute Respiratory"/>
 <result pre="Middle East Respiratory Syndrome RIG-I Retinoic acid-inducible gene I SARS" exact="Severe" post="Acute Respiratory Syndrome VEEV Venezuelan Equine Encephalitis Virus; Publisher’s"/>
 <result pre="East Respiratory Syndrome RIG-I Retinoic acid-inducible gene I SARS Severe" exact="Acute" post="Respiratory Syndrome VEEV Venezuelan Equine Encephalitis Virus; Publisher’s Note"/>
 <result pre="Respiratory Syndrome RIG-I Retinoic acid-inducible gene I SARS Severe Acute" exact="Respiratory" post="Syndrome VEEV Venezuelan Equine Encephalitis Virus; Publisher’s Note Springer"/>
 <result pre="Syndrome RIG-I Retinoic acid-inducible gene I SARS Severe Acute Respiratory" exact="Syndrome" post="VEEV Venezuelan Equine Encephalitis Virus; Publisher’s Note Springer Nature"/>
 <result pre="acid-inducible gene I SARS Severe Acute Respiratory Syndrome VEEV Venezuelan" exact="Equine" post="Encephalitis Virus; Publisher’s Note Springer Nature remains neutral with"/>
 <result pre="gene I SARS Severe Acute Respiratory Syndrome VEEV Venezuelan Equine" exact="Encephalitis" post="Virus; Publisher’s Note Springer Nature remains neutral with regard"/>
 <result pre="References 1.FuruyamaWMarziAEbola virus: pathogenesis and countermeasure developmentAnnu Rev Virol20196143545831567063 2.MussoDKoAIBaudDZika" exact="virus infection" post="- after the pandemicN Engl J Med2019381151444145731597021 3.Wang M,"/>
 <result pre="1.FuruyamaWMarziAEbola virus: pathogenesis and countermeasure developmentAnnu Rev Virol20196143545831567063 2.MussoDKoAIBaudDZika virus" exact="infection" post="- after the pandemicN Engl J Med2019381151444145731597021 3.Wang M,"/>
 <result pre="from: https://www.cdc.gov/flu/about/burden/index.html. 6.CDC. AIDS and HIV. Available from: https://www.cdc.gov/nchs/fastats/aids-hiv.htm. 7.CDC." exact="Hepatitis" post="B. Available from: https://www.cdc.gov/nchs/fastats/hepatitis.htm. 8.Fleming RW, Wenstrup DL, Andrews"/>
 <result pre="G, Tur'ianov M. [Evaluation of amyxin effect in prophylaxis of" exact="acute" post="respiratory viral infections]. Zhurnal mikrobiologii, epidemiologii, i immunobiologii. 2001(3):42–46."/>
 <result pre="Tur'ianov M. [Evaluation of amyxin effect in prophylaxis of acute" exact="respiratory" post="viral infections]. Zhurnal mikrobiologii, epidemiologii, i immunobiologii. 2001(3):42–46. 11.Anon."/>
 <result pre="M. [Evaluation of amyxin effect in prophylaxis of acute respiratory" exact="viral" post="infections]. Zhurnal mikrobiologii, epidemiologii, i immunobiologii. 2001(3):42–46. 11.Anon. Amixin."/>
 <result pre="effects of tilorone hydrochloride (analog 11,567) with inactivated Venezuelan equine" exact="encephalomyelitis" post="virus vaccine. Proceedings of the Society for Experimental Biology"/>
 <result pre="J Virol. 2019;93(12). 19.VarginVVZschiescheWSemenovBFEffects of tilorone hydrochloride on experimental flavivirus" exact="infections" post="in miceActa Virol197721211411817279 20.KarpovAVZholobakNMSpivakNYRybalkoSLAntonenkoSVKrivokhatskayaLDVirus-inhibitory effect of a yeast RNA-tilorone"/>
 <result pre="culturesActa Virol200145318118411774897 21.KuehneRWPannierWLStephenELEvaluation of various analogues of tilorone hydrochloride against" exact="Venezuelan equine encephalitis" post="virus in miceAntimicrob Agents Chemother19771119297836018 22.KaufmanHECentifantoYMEllisonEDBrownDCTilorone hydrochloride: human toxicity"/>
 <result pre="21.KuehneRWPannierWLStephenELEvaluation of various analogues of tilorone hydrochloride against Venezuelan equine" exact="encephalitis" post="virus in miceAntimicrob Agents Chemother19771119297836018 22.KaufmanHECentifantoYMEllisonEDBrownDCTilorone hydrochloride: human toxicity"/>
 <result pre="stimulationProc Soc Exp Biol Med197113713573605581674 23.SemenenkoTASelkovaEPNikitinaGYGotvyanskayaTPYudinaTIAmaryanMPNosikNNTuryanovMHImmunomodulators in the prevention of" exact="acute" post="respiratory viral infectionsRuss J Immunol20027210511412687252 24.SelkovaEPTur'ianovMCPantiukhovaTNNikitinaGISemenenkoTAEvaluation of amixine reactivity"/>
 <result pre="Soc Exp Biol Med197113713573605581674 23.SemenenkoTASelkovaEPNikitinaGYGotvyanskayaTPYudinaTIAmaryanMPNosikNNTuryanovMHImmunomodulators in the prevention of acute" exact="respiratory" post="viral infectionsRuss J Immunol20027210511412687252 24.SelkovaEPTur'ianovMCPantiukhovaTNNikitinaGISemenenkoTAEvaluation of amixine reactivity and"/>
 <result pre="Exp Biol Med197113713573605581674 23.SemenenkoTASelkovaEPNikitinaGYGotvyanskayaTPYudinaTIAmaryanMPNosikNNTuryanovMHImmunomodulators in the prevention of acute respiratory" exact="viral" post="infectionsRuss J Immunol20027210511412687252 24.SelkovaEPTur'ianovMCPantiukhovaTNNikitinaGISemenenkoTAEvaluation of amixine reactivity and efficacy"/>
 <result pre="Immunol20027210511412687252 24.SelkovaEPTur'ianovMCPantiukhovaTNNikitinaGISemenenkoTAEvaluation of amixine reactivity and efficacy for prophylaxis of" exact="acute" post="respiratory tract infectionsAntibiot Khimioter200146101418 25.Sel'kova EP, Iakovlev VN, Semenenko"/>
 <result pre="24.SelkovaEPTur'ianovMCPantiukhovaTNNikitinaGISemenenkoTAEvaluation of amixine reactivity and efficacy for prophylaxis of acute" exact="respiratory" post="tract infectionsAntibiot Khimioter200146101418 25.Sel'kova EP, Iakovlev VN, Semenenko TA,"/>
 <result pre="G, Tur'ianov M. [Evaluation of amyxin effect in prophylaxis of" exact="acute" post="respiratory viral infections]. Zh Mikrobiol Epidemiol Immunobiol. 2001(3):42–46. 26.Sel'kova"/>
 <result pre="Tur'ianov M. [Evaluation of amyxin effect in prophylaxis of acute" exact="respiratory" post="viral infections]. Zh Mikrobiol Epidemiol Immunobiol. 2001(3):42–46. 26.Sel'kova EP,"/>
 <result pre="M. [Evaluation of amyxin effect in prophylaxis of acute respiratory" exact="viral" post="infections]. Zh Mikrobiol Epidemiol Immunobiol. 2001(3):42–46. 26.Sel'kova EP, Semenenko"/>
 <result pre="28.ZakirovIGUse of amixin in the therapy and prevention of some" exact="viral" post="infectionsKlin Med (Mosk)200280125456 29.MadridPBChopraSMangerIDGilfillanLKeepersTRShurtleffACGreenCEIyerLVDilksHHDaveyRAKolokoltsovAACarrionRJrPattersonJLBavariSPanchalRGWarrenTKWellsJBMoosWHBurkeRLTangaMJA systematic screen of FDA-approved drugs"/>
 <result pre="Efficacy of Oral Pyronaridine Tetraphosphate and Favipiravir Against Ebola Virus" exact="Infection" post="in Guinea Pig Submitted. 2020. 34.Ekins S, Madrid PB."/>
 <result pre="expression: tilorone or its analogs are novel potent activators of" exact="hypoxia" post="inducible factor-1 that provide prophylaxis against stroke and spinal"/>
 <result pre="potent activators of hypoxia inducible factor-1 that provide prophylaxis against" exact="stroke" post="and spinal cord injuryAnn N Y Acad Sci2008114738339419076458 39.GaforioJJOrtegaEAlgarraISerranoMJAlvarez"/>
 <result pre="of phagocytic activity but not of proinflammatory cytokine (interleukin-6 [IL-6]," exact="tumor" post="necrosis factor alpha, and IL-12) production elicited in splenic"/>
 <result pre="elicited in splenic macrophages by tilorone treatment of mice during" exact="acute" post="systemic candidiasisClin Diagn Lab Immunol2002961282129412414762 40.LiuQZhouYHYangZQThe cytokine storm of"/>
 <result pre="in splenic macrophages by tilorone treatment of mice during acute" exact="systemic" post="candidiasisClin Diagn Lab Immunol2002961282129412414762 40.LiuQZhouYHYangZQThe cytokine storm of severe"/>
 <result pre="in murine models of infectionCell Rep201718381682928099857 45.MartinREMarchettiRVCowanAIHowittSMBroerSKirkKChloroquine transport via the" exact="malaria" post="parasite's chloroquine resistance transporterScience.200932559481680168219779197 46.GuptaDKGieselmannVHasilikAvon FiguraKTilorone acts as a"/>
 <result pre="M, Marsh M. Identification of Broad-Spectrum Antiviral Compounds by Targeting" exact="Viral" post="Entry. Viruses. 2019;11(2). 52.PecheurEIBorisevichVHalfmannPMorreyJDSmeeDFPrichardMMireCEKawaokaYGeisbertTWPolyakSJThe synthetic antiviral drug Arbidol inhibits"/>
</results>
